Relevium Medical

Chronic pelvic pain is a debilitating condition, that impacts over 15 million US women and costs over $39 Billion each year to manage. V-Flow medical has developed a trio of products that target the root cause of chronic pelvic pain, allowing millions of women to avoid opioid use and restart living a normal, pain free life. The V-Flow team has successfully scaled, multiple start-up medical device companies in various clinical disciplines with a combined exit value of over $4B. We have developed

shared product terms: medical, develop, pain, over; shared product theme: health and clinical care; shared affiliation: Y Combinator

SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis

shared product terms: disease, patient, strong, oral; shared product theme: health and clinical care; shared affiliation: Y Combinator

Amal's an investing app for Muslims. Muslims only invest in Shariah-compliant business, but it's hard to know which businesses are compliant. That's because it's based on complex financial metrics that change over time. We take that burden away entirely. Amal can filter stocks but also, remarkably, funds. Set your filters up once, and you'll have access to a universe of investments that cater to your specific requirements. Sign up today at https://amalinvest.com

shared product terms: but, because, over, time; shared affiliation: Y Combinator

We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.

shared product terms: develop, disease, patient, but; shared product theme: health and clinical care; shared affiliation: Y Combinator

Heart failure impacts millions worldwide and is associated with poor quality of life and high mortality rates. Because the heart cannot pump efficiently, fluids buildup around the body. Fluid overload is the main driver behind patient symptoms (shortness of breath, fatigue, chest pain, etc.) and hospitalizations. Our minimally invasive device leverages the body's innate fluid management system to offload trapped fluid and prevent subsequent rounds of buildup. The one-time procedure has sustained

shared product terms: pain, patient, because, time; shared product theme: health and clinical care; shared affiliation: Y Combinator

Craniometrix has raised over $21 million to help make dementia suck less. Dementia is tough – but it can be easier. Turns out, if you give families the right non-clinical coaching and support, you can avoid 30% of hospitalizations for these patients. And Medicare has recently started paying for that coaching. We launched our care navigation service for dementia patients in July of 2025, hit $8M of ARR, and just raised a $15M Series A. We leverage AI to provide best-in-class care, alleviating the

shared product terms: over, million, but, right; shared product theme: health and clinical care; shared affiliation: Y Combinator